Design of Lipid nanoparticle (LNP)- RNA vaccine against Haemophilus influenza type b hcsA and hcsB genes facilitating the transport of capsular polysaccharides across the outer membrane | ||
| International Journal of Health Sciences (Egypt) | ||
| Volume 1, Issue 3, October 2023, Pages 113-121 PDF (994.57 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ijhegy.2023.199193.1009 | ||
| Author | ||
| Mohammed M Kassab* | ||
| Instructor of microbiology,immunology,faculty of pharmacy,Cairo university,Egypt Specialist of pharmacology, toxicology and clinical pharmacy. | ||
| Abstract | ||
| Background: Hib-related meningitis and pneumonia are severe and debilitating infectious disorders that can affect anyone. The protection provided by the Haemophilus influenzae immunisation was long-lasting. Purpose of the research: The creation of a lipid nanoparticle (LNP) RNA vaccine against the genes hcsA and hcsB that allow the movement of capsular polysaccharides over the outer membrane in Haemophilus influenzae type b. Research type: Screening experimental study. Methodology: In this study, we created an LNP-RNA vaccine for Haemophilus influenzae type b hcsA and hcsB, which are involved in the pathogen's ability to transfer capsular polysaccharides through its outer membrane. Lipid nanoparticles with a particle diameter of roughly 87 nanometers made up the vaccine delivery system. Results: In preclinical experiments conducted on animals, the vaccine's efficacy was 91%, while in Phase 1/2 clinical trials, it was only about 85%. Compared to other conventional vaccines, it had superior biological activity and fewer adverse effects. Conclusion: In our investigation, the vaccination proved a promising and effective preventative measure against bacterial illness brought on by HA. | ||
| Keywords | ||
| Haemophilus influenza; vaccine; RNA; meningitis | ||
|
Statistics Article View: 209 PDF Download: 176 |
||
